Silexion Therapeutics

Company Overview

Snapshot

Founded in November 2008 by Amotz Shemi, PhD, Silexion Therapeutics operates with 11–50 employees. The company has raised $27.65 million across 6 funding rounds. Silexion Therapeutics became public on NASDAQ in August 2024.

Business overview

Silexion Therapeutics is a developmental stage company focused on creating innovative treatments for pancreatic cancer. Leveraging RNA interference technology, the company develops RNA-based therapeutics designed to silence specific genes implicated in pancreatic cancer growth and metastasis. Its core product, LODERTM, has shown positive efficacy results in Phase 2 clinical trials. Silexion Therapeutics is committed to enhancing its first-generation product and developing new formulations to improve clinical efficacy against pancreatic cancer, serving the oncology and pharmaceutical markets.

Strategic signal

In May 2026, Silexion Therapeutics announced the initiation of GMP clinical supply manufacturing for SIL204 with a leading global CDMO and received approval for a Phase 2/3 trial from Tel Aviv Sourasky Medical Center. This signals a significant advancement in the company's clinical development pipeline, indicating progress towards commercialization and validating its therapeutic approach for investors.

Company Intelligence Q&A

What is Silexion Therapeutics' primary focus?

Silexion Therapeutics is dedicated to the development of innovative treatments for pancreatic cancer, utilizing RNA interference technology to silence genes involved in cancer growth and metastasis.

When did Silexion Therapeutics become a public company?

Silexion Therapeutics became public on NASDAQ in August 2024.

What was a significant recent clinical development for Silexion Therapeutics?

In May 2026, Silexion Therapeutics announced the initiation of GMP clinical supply manufacturing of SIL204 and received approval for a Phase 2/3 trial from Tel Aviv Sourasky Medical Center.

What was the outcome of the Phase 2 trial for LODER™?

In September 2024, Silexion Therapeutics announced significant new data from the Phase 2 trial of LODER™ in non-resectable pancreatic cancer, showing positive efficacy results compared to chemotherapy alone.

What recent regulatory approval did Silexion Therapeutics receive for SIL204?

In June 2026, Silexion Therapeutics received approval from Germany's BfArM to initiate a Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer.